SPI and Neuralstem sign licensing agreement for major depression drug, NSI-189

Neuralstem, Inc. (NYSE Amex: CUR) announced that it has signed an exclusive agency licensing agreement with Summit Pharmaceuticals International Corporation, of Tokyo, Japan (SPI), a wholly owned subsidiary of Sumitomo Corporation Group.  Under the agreement, SPI will market development and licensing rights to NSI-189, Neuralstem's neurogenic compound, currently in an FDA-approved Phase I clinical trial for major depression.  

"We have stated previously our intention to take NSI-189 through Phase II trials before seeking a partner for worldwide rights," said Neuralstem President & CEO Richard Garr. "The single exception to this strategy is the Japanese market, where we are aggressively seeking an early-stage development and licensing partner. We look forward to working with Sumitomo to achieve this end."


Neuralstem, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Epigenetic modulators have a rapid antidepressant-like effect, study shows